KAPAHealthcare · BiotechnologyKAPA Stock Forecast: Kairos Pharma Ltd. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Kairos Pharma Ltd. hold a median 12-month price target of $7 — +2158.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KAPA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Kairos Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Momentum (6): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Kairos Pharma Ltd. — and when they’d sell — is the membership.
KAPA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KAPA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2158.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 31 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2025 | Maxim Group | Initiates | Buy | — |
| 20 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 22 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 14 Oct 2024 | EF Hutton | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KAPA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Kairos Pharma Ltd. (KAPA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.0×
- Price / sales
- —
- Price / book
- 1.2×
- EV / EBITDA
- −0.5×
Cheaper than 82% of US stocks
Cheaper than 65% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −93.8%
- Return on assets
- −54.8%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KAPA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KAPA appears on the weeks it earns a place.
Frequently asked questions about KAPA stock
What is the KAPA stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Kairos Pharma Ltd. have a median 12-month price target of $7, with estimates ranging from $2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KAPA stock a buy right now?
Of the 2 analysts covering Kairos Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kairos Pharma Ltd. 29 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KAPA?
As at 1 Aug 2026, Kairos Pharma Ltd. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
Will KAPA stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +2158.1% from the last close, and Ticker Nerd's factor model ranks Kairos Pharma Ltd. 29 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KAPA stock forecast for 2030?
No analyst covering Kairos Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KAPA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $12 over the next 12 months.
How has KAPA stock performed over the past year?
Kairos Pharma Ltd. returned -66.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kairos Pharma Ltd. do?
Kairos Pharma Ltd. is a pharmaceutical company focused on the research, development, and commercialization of innovative therapies.
About Kairos Pharma Ltd.
Kairos Pharma Ltd. is a pharmaceutical company focused on the research, development, and commercialization of innovative therapies. Its primary function is to advance treatments that target niche, unmet medical needs, particularly in the fields of oncology and degenerative diseases. The company is committed to harnessing cutting-edge scientific advancements and biotechnology, working alongside healthcare professionals and researchers to bring viable solutions to the market. Notable features include its robust pipeline of clinical trials that explore novel drug candidates and proprietary platforms aimed at improving patient outcomes. Kairos Pharma Ltd. plays a pivotal role in the healthcare sector, contributing to the development of new medications that offer hope to patients and healthcare providers alike. By addressing specialized medical demands, the company influences the pharmaceutical landscape and supports the ongoing evolution of targeted therapies.
CEO Dr. John S. Yu M.D., Ph.D. · 1 employees · United States · https://kairospharma.com